Related Experiment Video
Updated: Mar 12, 2026
Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
Published on: March 30, 2019
The Low Expression of IL-37 Involved in Multiple Myeloma - Associated Angiogenesis
Zun-Chang Li1, Ming-Dong Sun2, Yong-Qing Zheng2
1Department of Hemotology, Provincial Hospital, Shandong University, Jinan, Shandong, China (mainland).
Abstract:
BACKGROUND Angiogenesis plays a significant role in complex inflammatory and angiogenic processes and is also involved in multiple myeloma (MM) pathogenesis. IL-37 is a proinflammatory cytokine in antitumor activity. Our purpose was to evaluate the IL-37 clinical significance on MM. MATERIAL AND METHODS We measured serum levels of IL-37 in 45 patients with different stages of MM and 30 healthy control subjects and correlated IL-37 with numerous cytokines, such as angiogenesis factors including vascular endothelial growth factor (VEGF) and angiotensin-2 (Ang-2). We also measured the tube formation of human umbilical vein endothelial cells (HUVECs) after pretreatment with recombinant human IL-37 (rhIL-37). RESULTS Serum IL-37 level was lower in the patients with MM than in the healthy control subjects, whereas VEGF and Ang-2 levels were higher, depending on International Staging System stage. Serum IL-37 level had a negative correlation to VEGF and Ang-2 levels, and VEGF had a positive correlation to Ang-2 level. The tube formation of HUVECs was suppressed by the rhIL-37 pretreatment. CONCLUSIONS Our results indicate that serum level of IL-37 plays a part in the pathophysiology of MM progression. Therefore, IL-37 serum level may be a biomarker for disease stage and angiogenesis processes.
Insights
Serum IL-37 levels are lower in multiple myeloma (MM) patients, correlating negatively with angiogenesis factors like VEGF. IL-37 may serve as a biomarker for MM progression and angiogenesis.
Area of Science:
- Immunology
- Oncology
- Biochemistry
Background:
- Angiogenesis is crucial in inflammatory processes and multiple myeloma (MM) pathogenesis.
- Interleukin-37 (IL-37) is a proinflammatory cytokine with antitumor potential.
- The role of IL-37 in MM requires further clinical investigation.
Purpose of the Study:
- To assess the clinical significance of IL-37 in patients with multiple myeloma.
- To investigate the correlation between IL-37 levels and angiogenesis factors in MM.
- To determine the effect of IL-37 on endothelial cell function.
Main Methods:
- Serum IL-37, vascular endothelial growth factor (VEGF), and angiotensin-2 (Ang-2) levels were measured in 45 MM patients and 30 healthy controls.
- Correlations between IL-37, VEGF, Ang-2, and MM staging were analyzed.
- In vitro assays assessed the impact of recombinant human IL-37 (rhIL-37) on human umbilical vein endothelial cell (HUVEC) tube formation.
Main Results:
- MM patients exhibited lower serum IL-37 levels compared to healthy controls.
- VEGF and Ang-2 levels were elevated in MM patients, increasing with disease stage.
- Serum IL-37 negatively correlated with VEGF and Ang-2; VEGF positively correlated with Ang-2.
- rhIL-37 pretreatment suppressed HUVEC tube formation.
Conclusions:
- Serum IL-37 levels are implicated in the pathophysiology and progression of multiple myeloma.
- IL-37 may function as a potential biomarker for MM disease stage and associated angiogenesis.
- Targeting IL-37 could offer therapeutic strategies for managing MM-related angiogenesis.
More Related Videos
11:29Development of an Insert Co-culture System of Two Cellular Types in the Absence of Cell-Cell Contact
Published on: July 17, 2016
05:32Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
Published on: January 7, 2019
Related Concept Videos
01:24Regulation of Angiogenesis and Blood Supply
01:10Mechanism of Angiogenesis